Abstract: An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. In the hypothermic mode, the organ is perfused with a medical fluid, preferably a simple crystalloid solution containing antioxidants, intermittently or in slow continuous flow. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
January 8, 2013
Assignee:
Lifeline Scientific, Inc.
Inventors:
Donald R. Owen, David C. Kravitz, John Brassil, Kelvin G. M. Brockbank, Andrew Burroughs, Dickon Isaacs, Dennis J. Steibel, Richard Fraser, Stanley Harris, Douglas Schein
Abstract: Disclosed are freeze-dried plasma formats specifically designed for the trauma care field. Blood plasma is subjected to a glucose removal step, a protein fraction up-concentration step and addition of stabilizers prior to freeze-drying. Preferable stabilizers are glutamine dipeptides, glutamine and glycine. The glutamine based formulation is added direct to plasma and serves three main purposes: 1) Increases stability of plasma proteins and stabilizes pH in freeze-dried state; 2) Increases stability of plasma proteins against Gamma Irradiation and thus allows for the application of a terminal sterilization step; 3) Introduces supplements beneficial to the trauma patient.
Abstract: According to the present invention, by using 4-halogeno-3-hydroxybutanamide as a substrate in quaternary amination reaction with trialkylamine which is an important step in betaine (such as carnitine) preparation processes, it becomes possible to reduce the production of crotonic acid derivatives (the major by-product) greatly compared to conventional processes. Consequently, it becomes possible to prepare a betaine, such as carnitine, at a high yield.
Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.
Type:
Grant
Filed:
November 19, 2008
Date of Patent:
December 18, 2012
Assignee:
Instrumentation Laboratory Company
Inventors:
Yong Dai, Biqing Ye, Kui Chen, Pau Bruguera, Daniel Lawson, Shamay Tang
Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.
Abstract: An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
November 27, 2012
Assignee:
Lifeline Scientific, Inc.
Inventors:
Donald R. Owen, David C. Kravitz, John Brassil, Kelvin G. M. Brockbank, Andrew Burroughs, Dickon Isaacs, Dennis J Steibel, Richard Fraser, Stanley Harris, Douglas Schein, Christopher G. Curtis
Abstract: Disclosed is a method for processing porcine cornea using an aqueous NaCl solution and an aqueous trypsin/EDTA solution to decellularize enucleated porcine cornea. The porcine cornea processed by the method causes neither inflammation nor immune rejection. The porcine corneal stroma decellularized by the method can be recellularized together with host keratocytes after transplantation.
Type:
Grant
Filed:
October 15, 2009
Date of Patent:
November 20, 2012
Assignee:
SNU R&DB Foundation
Inventors:
Won-Ryang Wee, Mee-Kum Kim, Joo-Youn Oh
Abstract: This invention provides a solution for preserving mammalian early embryos or ES cells by vitrification, which comprises, as a base material, a phosphate buffer that exclusively contains 10% to 15% (v/v) propylene glycol as polyhydric alcohol or a phosphate buffer that exclusively contains 10% to 15% (v/v) propylene glycol and 25% to 35% (v/v) ethylene glycol as polyhydric alcohols and further contains 15% to 25% (v/v) Percoll® and 0.2 M to 0.5 M sucrose. This invention also provides a method for preserving mammalian early embryos or ES cells by vitrification using such solution.
Type:
Grant
Filed:
August 22, 2008
Date of Patent:
October 23, 2012
Assignee:
Central Institute for Experimental Animals
Abstract: Materials and methods for preserving biological materials (e.g., organs, tissues, and cells) under cold or cryo conditions while reducing or minimizing damage to the materials.
Abstract: The present invention relates to a method for improving viability and/or stress tolerance of viable biological material and using the said material comprising applying hydrostatic pressure to said biological material; keeping the said viable biological material at the hydrostatic pressure for a predetermined time period; releasing the hydrostatic pressure; and using the said material for any desired purpose in accordance with any useful protocol. The usage of the said biological material incorporates any techniques, protocols that are applicable in the field of assisted reproductive techniques, biotechnical and/or biotechnological manipulations.
Type:
Grant
Filed:
November 21, 2006
Date of Patent:
October 2, 2012
Assignee:
Cryo Management Kft.
Inventors:
Csaba Pribenszky, Miklós Molnár, András Horváth
Abstract: An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. In perfusion, organ perfusion pressure is preferably controlled in response to a sensor disposed in an end of tubing placed in the organ, by a pneumatically pressurized medical fluid reservoir, providing perfusion pressure fine tuning, overpressurization prevention and emergency flow cut-off.
Abstract: Methods of isolating cellular products, such as pancreatic islets, may be used in diabetes research and therapeutic transplantation. The methods may involve providing a tissue having desired cells that are less prone to destructive freezing and undesired cells that are more prone to destructive freezing, or pre-treating a tissue to have such characteristics. The methods may involve freezing the tissue, disrupting the tissue, warming the tissue, and separating the desired cells from undesired cellular material to obtain the cellular product. The methods may thereby provide an enzyme-free or reduced-enzyme method of isolating a cellular product that is more consistent, reliable and less toxic than conventional methods. The methods may also yield an optimum quantity of cellular product that retain sufficient functional integrity to be useful as a transplantation resource.
Abstract: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.
Type:
Grant
Filed:
August 26, 2009
Date of Patent:
August 28, 2012
Assignees:
Kowa Company, Ltd., Nissan Chemical Industries, Ltd.
Abstract: Flush preservation solution for the preservation of cells in the absence of a blood supply comprising: v) water for injection; and vi) at least one saccharide such as a monosaccharide, disaccharide, trisaccharide, or polysaccharide and vii) at least one component with pH buffer properties; and viii) at least one component with calcium transport blocking properties or an anti-calcium action activity; method for the preparation thereof; use thereof in transplantation including organs from heart beating or non heart beating donors, in surgery including any situation of warm or cold ischaemia, cardioplegia or open heart surgery, whole limb or whole body preservation in experimentation on living tissues or in culturing and preserving engineered cells, tissues and organs, limbs or the whole body; method for flushing, preserving or flush preservation of cells; and a kit of parts comprising the solution components.
Abstract: A BUN (blood urea nitrogen) sensor containing immobilized carbonic anhydrase and immobilized urease for the in vitro detection of urea nitrogen in blood and biological samples with improved performance and precision characteristics.
Type:
Grant
Filed:
February 25, 2009
Date of Patent:
August 7, 2012
Assignee:
Abbott Point of Care Inc.
Inventors:
G. Bruce Collier, Eric Brouwer, Anjulia Wong
Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.
Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.
Type:
Grant
Filed:
July 14, 2008
Date of Patent:
July 17, 2012
Assignee:
Velico Medical, Inc.
Inventors:
Keith M. Rosiello, Henrik Clausen, Hans Wandall, Thomas P. Stossel, John H. Hartwig, Karin M. Hoffmeister
Abstract: Methods and compositions for resuscitating, storing, and preserving functional integrity of organs and tissues. Metabolic function is maintained by sustaining ATP levels, mitochondrial function, cardiomyocyte contractility, prevention of acidosis, inhibition of induction of apoptosis, maintaining ionontrophy and lusiotrophy by regulating calcium, sodium, potassium and chloride ions.
Type:
Grant
Filed:
February 19, 2008
Date of Patent:
July 3, 2012
Assignees:
President and Fellows of Harvard College, The United States of America as Represented by the Department of Veterans Affairs
Inventors:
Hemant Thatte, Patrick Treanor, Shukri F. Khuri, Randa Khuri, legal representative, Laki Rousou
Abstract: A method for improving the bioavailability of polysaccharides in lignocellulosic materials, involving reacting lignocellulosic materials with ammonia and ethanol.
Type:
Grant
Filed:
August 20, 2008
Date of Patent:
June 19, 2012
Assignee:
The United States of America, as represented by the Secretary of Agriculture
Inventors:
Nhuan P. Nghiem, Tae H. Kim, Kevin B. Hicks
Abstract: A process for the production of an optically enriched tertiary alcohol of the formula (2a) or (2b), by reacting an epoxide of the formula (1) with a nucleophilic agent Nu in the presence of halohydrin dehalogenase.
Type:
Grant
Filed:
December 13, 2006
Date of Patent:
June 12, 2012
Assignee:
BASF SE
Inventors:
Bernhard Hauer, Dick B. Janssen, Maja Majeric-Elenkov